Abstract
The aim of reverse pharmacognosy is to find new biological targets for natural compounds by virtual or real screening and identify natural resources that contain the active molecules. To demonstrate the applicability of this concept, we report here a study on εviniferin, an active ingredient for cosmetic development. Nevertheless, this natural substance is weakly defined in terms of biological properties. SELNERGY, an inverse docking computer software, was used to identify putative binding biological targets for εviniferin. Among the 400 screened proteins two targets were retained. For cosmetic application, cyclic nucleotide phosphodiesterase 4 (PDE4) was the most interesting candidate. Moreover, other PDE subtypes (1, 2, 3, 5 and 6) were not retained, indicating a selectivity for PDE4. The experimental binding tests on the 6 subtypes of PDE revealed a significant selectivity of εviniferin for the PDE4 subtype. This selectivity was confirmed by evaluation of εviniferin on the secretion of TNF-α and Interleukin-8. Our data demonstrated that εviniferin possesses anti-inflammatory properties by inhibiting PDE4 subtype. In conclusion, reverse pharmacognosy and its inverse docking component cannot only be integrated into a program for new lead discovery but is also a useful approach to find new applications for identified compounds.
Keywords: Inverse docking, cosmetics, cyclic nucleotide phosphodiesterases, viniferin, selnergy
Current Drug Discovery Technologies
Title: Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin
Volume: 2 Issue: 3
Author(s): Quoc-Tuan Do, Isabelle Renimel, Patrice Andre, Claire Lugnier, Christian D. Muller and Philippe Bernard
Affiliation:
Keywords: Inverse docking, cosmetics, cyclic nucleotide phosphodiesterases, viniferin, selnergy
Abstract: The aim of reverse pharmacognosy is to find new biological targets for natural compounds by virtual or real screening and identify natural resources that contain the active molecules. To demonstrate the applicability of this concept, we report here a study on εviniferin, an active ingredient for cosmetic development. Nevertheless, this natural substance is weakly defined in terms of biological properties. SELNERGY, an inverse docking computer software, was used to identify putative binding biological targets for εviniferin. Among the 400 screened proteins two targets were retained. For cosmetic application, cyclic nucleotide phosphodiesterase 4 (PDE4) was the most interesting candidate. Moreover, other PDE subtypes (1, 2, 3, 5 and 6) were not retained, indicating a selectivity for PDE4. The experimental binding tests on the 6 subtypes of PDE revealed a significant selectivity of εviniferin for the PDE4 subtype. This selectivity was confirmed by evaluation of εviniferin on the secretion of TNF-α and Interleukin-8. Our data demonstrated that εviniferin possesses anti-inflammatory properties by inhibiting PDE4 subtype. In conclusion, reverse pharmacognosy and its inverse docking component cannot only be integrated into a program for new lead discovery but is also a useful approach to find new applications for identified compounds.
Export Options
About this article
Cite this article as:
Do Quoc-Tuan, Renimel Isabelle, Andre Patrice, Lugnier Claire, Muller D. Christian and Bernard Philippe, Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin, Current Drug Discovery Technologies 2005; 2 (3) . https://dx.doi.org/10.2174/1570163054866873
DOI https://dx.doi.org/10.2174/1570163054866873 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heterogeneity in the Pathology and Molecular Biology of Breast Cancer
Current Genomics Urinary Tract Tumors, Biology and Risk for Artificial Sweeteners Use with Particular Emphasis on some South American Countries
Current Nutrition & Food Science Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design MicroRNAs in the Pathobiology of Multiple Myeloma
Current Cancer Drug Targets Induction of Autophagic Cell Death in Apoptosis-resistant Pancreatic Cancer Cells using Benzo[α]phenoxazines Derivatives, 10-methyl-benzo[α]phenoxazine-5-one and benzo[α]phenoxazine-5-one
Anti-Cancer Agents in Medicinal Chemistry <sup>109</sup>Pd labeled 5,10,15,20-tetrakis[4-carboxymethyleneoxyphenyl]porphyrin: a Potential Agent for Targeted Tumor Therapy
Current Radiopharmaceuticals Pleiotropic Effects of Cardioactive Glycosides
Current Medicinal Chemistry mRNA as a Versatile Tool for Exogenous Protein Expression
Current Gene Therapy Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer
Current Drug Targets Biology of Protooncogene c-kit Receptor and Spermatogenesis
Current Pharmacogenomics Interactions of Phenothiazines with Lipid Bilayer and their Role in Multidrug Resistance Reversal
Current Drug Targets Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design Management of Adult Active Tuberculosis Disease in Era of HIV Pandemic, Current Practices and Future Perspectives
Infectious Disorders - Drug Targets Neural Differentiation and Therapeutic Potential of Adipose Tissue Derived Stem Cells
Current Stem Cell Research & Therapy Crystallization and Preliminary Crystallographic Studies of an Antitumour Lectin from the Edible Mushroom Agrocybe aegerita
Protein & Peptide Letters Pyrrolo[2,1-c][1,4]benzodiazepine as a Scaffold for the Design and Synthesis of Anti- Tumour Drugs
Anti-Cancer Agents in Medicinal Chemistry Antisense Oligonucleotides as a Powerful Molecular Strategy for Gene Therapy in Cardiovascular Diseases
Current Pharmaceutical Design Shared Signaling Pathways Between Endocrine and Immune System Receptors: The Model of Gamma Chain
Current Signal Transduction Therapy Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry